Treatment-resistant prurigo nodularis: challenges and solutions

Area of Science:

• Dermatology
• Clinical Medicine
• Pathophysiology

Background:

• Prurigo nodularis (PN) is a chronic dermatosis characterized by intensely itchy papules and nodules.
• It can be a manifestation of underlying conditions like atopic dermatitis or chronic kidney disease, but also a distinct entity.
• The exact mechanisms of pruritus in PN, involving neuronal and inflammatory factors, are still under investigation.

Purpose of the Study:

• To review recent advancements in the treatment of Prurigo nodularis.
• To highlight emerging therapeutic strategies for managing this chronic pruritic condition.

Main Methods:

• A PubMed/MEDLINE search was conducted for studies on Prurigo nodularis treatments.
• Review of recent developments in therapeutic approaches for PN.

Main Results:

• Current treatments often involve topical/intralesional steroids, phototherapy, or systemic immunosuppressants.
• Thalidomide and lenalidomide are options for severe cases but have significant toxicity.
• Opioid receptor antagonists and neurokinin-1 receptor antagonists show promise as novel treatments with improved safety profiles.

Conclusions:

• Identifying and addressing underlying causes of PN is crucial for preventing recurrence.
• Multimodal treatment approaches are typically required due to comorbidities.
• Novel agents like opioid and neurokinin-1 receptor antagonists represent a promising direction for managing PN, offering potentially better safety than existing options.